IDEXX Laboratories (IDXX) has integrated its SDMA kidney biomarker, an early kidney disease detector, into its most popular point-of-care chemistry profiles, Catalyst CLIPs. This integration will be rolled out to customers in the US and Canada at no additional cost, providing veterinarians with earlier detection capabilities compared to traditional methods. The move aims to scale the impact of IDEXX's diagnostic innovations through platforms veterinarians already utilize daily.

Stifel analyst Jonathan Block reconfirmed a Buy rating and $210 price target for Align Technology (ALGN) after reviewing an updated financial model and the company's latest 10-Q filing. The updated model incorporated recent clear aligner volume data and Align's Q1 2026 earnings report, which showed revenue of $1.04 billion, a 6.2% year-over-year increase, attributed to record clear aligner shipments and higher selling prices. The company's GAAP EPS for Q1 2026 was $1.57 per diluted share, up from $1.26 in Q1 2025, driven by improved gross margins, a lower tax rate, and share buybacks.

Goldman Sachs reinstated coverage on Medtronic plc (MDT) with a Neutral rating and an $84 price target, noting the stock is appropriately priced at a 10% discount to its large-cap MedTech peers. The firm projects Medtronic's organic revenue to grow in line with the sector average of 5%, but expects more modest earnings growth due to a less favorable product mix for margin expansion. This suggests Medtronic needs stronger top-line growth to achieve comparable bottom-line lift relative to competitors.

William Blair analyst Steve Lichtman initiated coverage on Insulet (PODD) with an Outperform rating, citing the company's attractive valuation after a significant selloff despite near-term growth risks. Lichtman highlighted Insulet's strong revenue trajectory compared to peers, alongside catalysts like salesforce expansion and product development, as reasons for a stronger bull case. However, he also noted potential concerns regarding increased competition and uncertainty about Insulet's ability to capture the type 2 diabetes patient population due to the rise of GLP-1 drugs.

Heico Corp (HEI.A) reported record financial results for Q2 2026, with net income surging by 49% to $233.8 million, or $1.66 per diluted share, significantly exceeding analyst expectations. The company also saw a 25% increase in net sales to $1,375.7 million and strong operating income growth, reaffirming its robust performance in the aerospace and defense industry despite rising costs and increased debt from acquisitions. GuruFocus data indicates that HEI.A is currently undervalued, presenting a potential investment opportunity.

Ecolab Inc (ECL) shares rallied 3.3% to $262.58 but are still considered undervalued by 0.8% according to GuruFocus' GF Value, which stands at $264.61. The company boasts a strong GF Score of 88/100, indicating potential for long-term returns, and its current P/E ratio is below its historical median. Insider buying activity further suggests confidence in Ecolab's future prospects.

The article highlights how Phillips 66's legal department, led by General Counsel Vanessa Sutherland and Director of Legal Operations Michael Voutsinas, has dramatically upgraded its legal operations. This transformation, focusing on financial management, technology adoption, and vendor management, has earned them the 2026 Houston Corporate Counsel Award for Legal Innovation. Sutherland and Voutsinas discuss their strategies for fostering innovation and efficiency, including a revamped outside counsel engagement process and the integration of AI tools.

Principal's latest Business Owner Insights survey reveals that while business protection remains the top priority for small and midsize business owners, key employee benefits have surged to second place due to rising healthcare costs. Success planning and estate planning are also gaining importance for 2026. The survey highlights key areas for advisors to discuss with their business owner clients.

Synopsys shares experienced a slight dip in extended trading despite surpassing Wall Street's expectations for both its first-quarter results and full-year guidance. The company also announced the addition of activist investor Jesse Cohn to its board, a move that could influence its long-term strategy and value creation.

Salesforce (CRM) reported a 50% year-over-year increase in earnings per share for its first fiscal quarter of 2027. Despite the strong earnings, the company's shares dropped approximately 3% in post-market trading due to second-quarter revenue guidance that fell short of expectations. Salesforce's AI initiatives, Agentforce and Data 360, are performing well, with annual recurring revenue growing 200% year-over-year to $3.4 billion, and the company announced a new $25 billion share repurchase plan.